title: Insulin requirements after liver transplantation and FK-506 immunosuppression.
abstract: Hyperglycemia and new-onset diabetes mellitus is a well-recognized complication of solid organ transplantation. With the advent of FK-506 as a new immunosuppressive drug used in orthotopic liver transplantation (OLT), much attention has been paid to its diabetogenic effects. Currently, there are no data on the long term effects of FK-506 in glucose metabolism after OLT. In the present study, we determined the need for outpatient insulin in 52 American veterans who received 58 liver transplants using primary immunosuppression with FK-506 and PRED, with a mean follow-up of 467 days (range 17-952 days). We also analyzed their plasma glucose and FK-506 levels as well as the doses of PRED and FK-506 that they received at various intervals post-OLT. There were 7/52 (13.6%) patients who required insulin for the first time after OLT. Of these, the number of patients on insulin at 3, 6, and 12 months post-OLT was 5/47 (10.6%), 6/44 (13.6%), and 1/26 (3.8%), with none requiring insulin de novo at 18, 24, and 30 months post-OLT. Three patients required insulin temporarily but subsequently became normoglycemic without additional therapy. The need for insulin was not related to the dose of FK-506 administered nor the plasma level. Patients who required outpatient insulin were receiving higher doses of PRED than those not requiring insulin. The need for insulin did not affect the long-term graft or patient survival. In conclusion, the need for insulin with FK-506 compares favorably to that of previous immunosuppressive regimens, and FK-506 may have a reversible diabetogenic effect that is not dose dependent.
authors.affiliation: Division of Gastroenterology and Hepatology, University Health Center of Pittsburgh, Pennsylvania.
authors.forename: J
authors.initials: J
authors.lastname: Tabasco-Minguillan
authors.forename: L
authors.initials: L
authors.lastname: Mieles
authors.forename: P
authors.initials: P
authors.lastname: Carroll
authors.forename: J
authors.initials: J
authors.lastname: Gavaler
authors.forename: D H
authors.initials: DH
authors.lastname: Van Thiel
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D007328:Insulin; D016559:Tacrolimus